MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype

摘要: // Wei Yan 1, 2, * , Yanwei Liu 3, 4, Pei Yang 4 Zheng Wang Yongping You 2 Tao Jiang 1 Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China Department of Neurosurgery, First Affiliated Hospital Nanjing Nanjing, 3 Institute for Brain Disorders, Tumor Center, Tiantan Hospital, These authors have contributed equally to this work Correspondence to: Jiang, e-mail: taojiang1964@163.com You, yypl9@njmu.edu.cn Keywords: glioblastoma, microRNA, IDH1 mutation, temozolomide Received: December 16, 2014      Accepted: January 30, 2015      Published: March 23, 2015 ABSTRACT Accumulating evidence demonstrates that defining molecular subtypes based on objective genetic alterations may permit a more rational, patient-specific approach targeted therapy across various cancers. The study was subtype primary glioblastoma (pGBM) MicroRNA (miRNA) profiling in Chinese population. Here, miRNA expression profiles from 82 pGBM samples were analyzed and 78 independent used qRT-PCR validation. We found two distinct subgroups with different prognosis chemosensitivities (TMZ) samples. One is TMZ chemoresistant (termed the TCR subtype) confers poor prognosis. other TMZ-chemosensitive TCS relatively better compared subtype. A classifier consisting seven miRNAs then identified (miR-1280, miR-1238, miR-938 miR-423-5p (overexpressed subtype); let-7i, miR-151-3p miR-93 (downregulated subtype)), which could be assign corresponding validated using both internal external Meanwhile, also analyzed. characterized by no EGFR Ki-67 overexpression. displayed opposite situation. Taken together, results indicate subgroup TMZ-chemoresistance.